hereditary disease
The technology has been licensed by MGeneRx, which plans to commercialize it in the US first, then expand to low- and middle-income countries.
Centogene Q2 Revenues Continue to Benefit From COVID-19 Testing as Core Business Starts to Recover
The German rare disease diagnostics company had €51.9 million in Q2 revenues, significantly beating the average Wall Street estimate.
Centogene Q1 Revenues Grow More Than Fivefold Driven by COVID-19 Testing
Core diagnostic testing revenues were €6.4 million, down 15 percent year over year, while pharmaceutical revenues totaled €3.6 million, down 22 percent.
Natera Revenues Grow 35 Percent in Q4
The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.
German Medical Center to Report Polygenic Risk Scores as Part of Clinical Whole-Genome Testing
Premium
Under the Ge-Med project, University Hospital Tübingen will offer diagnostic whole-genome sequencing for all genetic indications and will include PRS in its reporting.
Jun 15, 2020
Centogene Q1 Revenues Increase 13 Percent
Jan 22, 2020
Quest Diagnostics Acquires Blueprint Genetics
Oct 3, 2019